{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:51Z","timestamp":1791357471174,"version":"4.3.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this study was to evaluate the effectiveness and safety of antipsychotic and antidepressant medications in individuals with 22q11.2 deletion syndrome (22q11.2 DS) and psychiatric comorbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We used a record review, structured clinical interviews, and the Clinical Global Impressions (CGI) scale to retrospectively assess the effectiveness and safety of antipsychotic medications for schizophrenia spectrum disorders and of antidepressant medications for depressive and anxiety disorders in 40 individuals with 22q11.2DS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We observed significant improvement in CGI-Severity scores in individuals with 22q11.2DS treated with antipsychotic or antidepressant medications, and a \u223c50% response rate based on the CGI-Improvement score. Adverse events were similar in types and rates to those reported in non-22q11.2 individuals treated with antipsychotics or antidepressants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our data show that treatment with antipsychotics and antidepressants may be effective while being relatively safe in individuals with 22q11.2DS. Antipsychotic and antidepressant medications should be considered in any individual with 22q11.2DS who has a psychiatric morbidity, such as psychosis or mood or anxiety disorders. Although the psychotropic medications were generally well tolerated in our sample, more rigorous metabolic and cardiovascular measures are required in future studies to conclusively verify the safety of these medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2014.0075","type":"journal-article","created":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T16:34:09Z","timestamp":1435768449000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":37,"title":["The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome"],"prefix":"10.1177","volume":"27","author":[{"given":"Netta","family":"Dori","sequence":"first","affiliation":[{"name":"Beer Yaakov-Ness Ziona Mental Health Center","place":["Israel"]},{"name":"Tel Aviv University","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Green","sequence":"additional","affiliation":[{"name":"Tel Aviv University","place":["Israel"]},{"name":"Stanford University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[{"name":"Tel Aviv University","place":["Israel"]},{"name":"Geha Mental Health Center","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Gothelf","sequence":"additional","affiliation":[{"name":"Tel Aviv University","place":["Israel"]},{"name":"Edmond and Lily Safra Children's Hospital","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"key":"e_1_3_2_2_1","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders 4th ed. (DSM-IV). Washington DC: American Psychiatric Association; 1994."},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.30984"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CHI.0000037049.04952.9F"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.09.019"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.1.101"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0013"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01231-8"},{"key":"e_1_3_2_9_1","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study","volume":"49","author":"Findling RL","year":"2010","unstructured":"Findling RL, , Johnson JL, , McClellan J, , Frazier JA, , Vitiello B, , Hamer RM, , Lieberman JA, , Ritz L, , McNamara NK, , Lingler J, et al.: Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry, 49:583\u2013594, 2010.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_2_10_1","unstructured":"First MG M. Spitezer R. Williams J: User's Guide for the Structural Clinical Interview for DSM-IV Axis I DisordersYResearch Version. New York: Biometric Research; 1996"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.2044"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00114-5"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1004"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.20124"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.08.008"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e3181b76683"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0042"},{"key":"e_1_3_2_18_1","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976","unstructured":"Guy W: Clinical Global Impressions Scale. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: United States Department of Health, Education, and Welfare; 1976"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-7-201210020-00525"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60486-9"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199707000-00021"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.05.011"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.10.1132"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(10)62223-0"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.6.e104"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.7.1050"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000336756.65308.83"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70415-4"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1062700"},{"key":"e_1_3_2_30_1","first-page":"S8","article-title":"Pharmacologic agents associated with QT interval prolongation","author":"Olsen KM","year":"2005","unstructured":"Olsen KM: Pharmacologic agents associated with QT interval prolongation. J Fam Pract, Suppl:S8\u2013S14, 2005.","journal-title":"J Fam Pract"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.34.10.798"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070864"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.048223-0"},{"key":"e_1_3_2_34_1","first-page":"179","article-title":"Psychometric properties of the K-SADS-PL in an Israeli adolescent clinical population","volume":"34","author":"Shanee N","year":"1997","unstructured":"Shanee N, , Apter A, , Weizman A: Psychometric properties of the K-SADS-PL in an Israeli adolescent clinical population. Isr J Psychiatry Relat Sci, 34:179\u2013186, 1997.","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2779(2000)6:2<142::AID-MRDD9>3.0.CO;2-H"},{"key":"e_1_3_2_36_1","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)","volume":"1","author":"Soomro GM","year":"2008","unstructured":"Soomro GM, , Altman D, , Rajagopal S, , Oakley\u2013Browne M: Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev, 1:CD001765, 2008.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_37_1","first-page":"305","article-title":"Anxiety disorders and perceptual disturbances in adolescents with 22q11.2 deletion syndrome treated with SSRI: A case series","volume":"20","author":"Stachon AC","year":"2011","unstructured":"Stachon AC, , De Souza C: Anxiety disorders and perceptual disturbances in adolescents with 22q11.2 deletion syndrome treated with SSRI: A case series. J Can Acad Child Adolesc Psychiatry, 20:305\u2013310, 2011.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291713001669"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.33.8.719"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.11.1153"},{"key":"e_1_3_2_41_1","doi-asserted-by":"crossref","unstructured":"Wechsler D: Wechsler Adult Intelligence Scale for Children: Third Edition Mannual. San Antonio: The Psychological Corporation; 1997.","DOI":"10.1037\/t49755-000"},{"key":"e_1_3_2_42_1","unstructured":"Wechsler D: Wechsler Intelligence Scale For Children 3rd ed. San Antonio TX: The Psychological Corporation; 1991"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2014.0075","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2014.0075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2014.0075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:59:06Z","timestamp":1779692346000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2014.0075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1089\/cap.2014.0075"],"URL":"https:\/\/doi.org\/10.1089\/cap.2014.0075","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}